Research programme: obesity therapies - Chong Kun Dang Pharmaceutical
Latest Information Update: 13 May 2010
At a glance
- Originator Chong Kun Dang
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 10 Sep 2007 Preclinical trials in Obesity in South Korea (unspecified route)